Cyclosporin-A Enhances Docetaxel-Induced Apoptosis through Inhibition of Nuclear Factor-κB Activation in Human Gastric Carcinoma Cells

Clinical Cancer Research

Volumn 9, Issue 14, 2003, Pages 5409-5416

  Nakahara, Chihiro ^a   Nakamura, Katsuya ^a   Yamanaka, Naoki ^a   Baba, Eishi ^a   Wada, Morimasa ^a   Matsunaga, Hisashi ^b   Noshiro, Hirokazu ^a   Tanaka, Masao ^a   Morisaki, Takashi ^a   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CYCLOSPORIN A; DOCETAXEL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; DRUG TRANSPORT; ENZYME ACTIVATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; GENE TRANSLOCATION; GENETIC TRANSDUCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; CYCLOSPORINE; DRUG COMBINATIONS; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NF-KAPPA B; PERITONEAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; STOMACH NEOPLASMS; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 10744222962     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Pisani, P., Parkin, D. M., Bray, F., and Ferlay, J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83: 18-29, 1999.
2. Tunaci, M. Carcinoma of stomach and duodenum: radiologic diagnosis and staging. Eur. J. Radiol., 42: 181-192, 2002.
3. Shimada, K., and Ajani, J. A. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer (Phila.). 86: 1657-1668, 1999.
4. Kim, R., Ohi, Y., Inoue, H., and Toge, T. Taxotere activates transcription factor AP-1 in association with apoptotic cell death in gastric cancer cell lines. Anticancer Res., 19: 5399-5405, 1999.
5. Schiff, P. B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
6. Bissery, M. C., Nohynek, G., Sanderink, G. J., and Lavelle, F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I. Preclinical experience. Anticancer Drugs, 6: 339-355, 363-368, 1995.
7. Naito, M., Matsuba, Y., Sato, S., Hirata, H., and Tsuruo, T. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin. Cancer Res., 8: 582-588, 2002.
8. Sjostrom, J., Blomqvist, C., von Boguslawski, K., Bengtsson, N. O., Mjaaland, I., Malmstrom, P., Ostenstadt, B., Wist, E., Valvere, V., Takayama, S., Reed, J. C., and Saksela, E. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin. Cancer Res., 8: 811-816, 2002.
9. Liu, B., Staren, E. D., Iwamura, T., Appert, H. E., and Howard, J. M. Mechanisms of Taxotere-related drug resistance in pancreatic carcinoma. J. Surg. Res., 99: 179-186, 2001.
10. waf-1 expression correlates with apoptosis or cell survival in poorly differentiated, but not well-differentiated, retinoblastomas. Cancer Res., 61: 3157-3163, 2001.
11. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
12. Labialle, S., Gayet, L., Marthinet, E., Rigal, D., and Baggetto, L. G. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem. Pharmacol., 64: 943-948, 2002.
13. Scatena, C. D., Stewart, Z. A., Mays, D., Tang, L. J., Keefer, C. J., Leach, S. D., and Pietenpol, J. A. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. Biol. Chem., 273: 30777-30784, 1998.
14. Vilenchik, M., Raffo, A. J., Benimetskaya, L., Shames, D., and Stein, C. A. Antisense RNA down-regulation of bcl-xL expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. Cancer Res., 62: 2175-2183, 2002.
15. Catz, S. D., and Johnson, J. L. Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer. Oncogene, 20: 7342-7351, 2001.
16. Oya, M., Ohtsubo, M., Takayanagi, A., Tachibana, M., Shimizu, N., and Murai, M. Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene, 20: 3888-3896, 2001.
17. Bharti, A. C., and Aggarwal, B. B. Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem. Pharmacol., 64: 883-888, 2002.
18. Sasaki, N., Morisaki, T., Hashizume, K., Yao, T., Tsuneyoshi, M., Noshiro, H., Nakamura, K., Yamanaka, T., Uchiyama, A., Tanaka, M., and Katano, M. Nuclear factor-κB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin. Cancer Res., 7: 4136-4142, 2001.
19. Deeg, M. J., Strob, R., Thomas, E. D., Flournoy, N., Kennedy, M. S., Banaji, M., Appelbaum, F. R., Bensinger, W. I., Bucker, C. D., Clift, R. A., Doney, K., Fefer, A., McGuffin, R., Sanders, J. E., Singer, J., Stewart, P., Sullivan, K. M., and Witherspoon, R. P. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood, 65: 1325-1334, 1985.
20. Goto, T., Kino, T., Hatanaka, H., Nishiyama, M., Okuhara, M., Kohsaka, M., Aoki, H., and Imanaka, H. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant. Proc., 19 (Suppl. 6): 4-8, 1987.
21. Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., and Schreiber, S. L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell, 66: 807-815, 1991.
22. Sigal, N. H., and Dumont, F. J. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu. Rev. Immunol., 10: 519-560, 1992.
23. Altavilla, D., Saitta, A., Guarini, S., Galeano, M., Squadrito, G., Santamaria, L. B., Venuti, F. S., Bazzani, C., Bertolini, A., and Squardrito, F. Nuclear factor-κB as a target of cyclosporin in acute hypovolemic hemorrhagic shock. Cardiovasc. Res., 52: 143-152, 2001.
24. Morisaki, T., Matsunaga, H., Beppu, K., Ihara, E., Hirano, K., Kanaide, H., Mori, M., and Katano, M. A combination of cyclosporin-A (CsA) and interferon-γ (IFN-γ) induces apoptosis in human gastric carcinoma cells. Anticancer Res., 20: 3363-3373, 2000.
25. Tsukahara, Y., Morisaki, T., Horita, Y., Torisu, M., and Tanaka, M. Phospholipase A2 mediates nitric oxide production by alveolar macrophages and acute lung injury in pancreatitis. Ann. Surg., 229: 385-392, 1999.
26. Chen, F. E., Huang, D. B., Chen, Y. Q., and Ghosh, G. Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA. Nature (Lond.), 391: 410-413, 1998.
27. Morishita, R., Sugimoto, T., Aoki, M., Kida, I., Tomita, N., Moriguchi, A., Maeda, K., Sawa, Y., Kaneda, Y., Higaki, J., and Ogihara, T. In vivo transfection of cis element "decoy" against nuclear factor-κB binding site prevents myocardial infarction. Nat. Med., 8: 894-899, 1997.
28. Vos, I. H., Govers, R., Grone, H. J., Kleij, L., Schurink, M., De Weger, R. A., Goldschmeding, R., and Rabelink, T. J. NF-κB decoy oligodeoxynucleotide reduce monocyte infiltration in renal allografts. FASEB J., 14: 815-822, 2000.
29. Kojima, M., Morisaki, T., Isuhara, K., Uchiyama, A., Matsunari, Y., Katano, M., and Tanaka, M. Lipopolysaccharide increases cyclooxygenase-2 expression in a colon carcinoma cell line through nuclear factor-κB activation. Oncogene, 19: 1225-1231, 2000.
30. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
31. O'Neill, G. P., and Ford-Hutchinson, A. W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett., 330: 156-160, 1993.
32. Nakayama, M., Wada, M., Harada, T., Nagayama, J., Kusaba, H., Ohshima, K., Kozuru, M., Komatsu, H., Ueda, R., and Kuwano, M. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood, 92: 4296-4307, 1998.
33. Matsunaga, H., Katano, M., Saita, T., Yamamoto, H., and Mori, M. Potentiation of cytotoxity of mitomycin C by a polyacetylenic alcohol, panaxytriol. Cancer Chemother. Pharmacol., 33: 291-297, 1994.
34. Ciccolini, J., Catalin, J., Blachon, M. F., and Durand, A. Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction. J. Chromatogr. B Biomed. Sci. Appl., 759: 299-306, 2001.
35. Garg, M. B., and Ackland, S. P. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J. Chromatogr. B Biomed. Sci. Appl., 748: 383-388, 2000.
36. den Hartigh, J., McVie, J. G., van Oort, W. J., and Pinedo, H. M. Pharmacokinetics of mitomycin C in humans. Cancer Res., 43: 5017-5021, 1983.
37. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Wash. DC), 274: 784-787, 1996.
38. Cusack, J. C., Jr., Liu, R., Houston, M., Abendroth, K., Elliott, P. J., Adams, J., and Baldwin, A. S., Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res., 61: 3535-3540, 2001.
39. Tan, C., and Waldmann, T. A. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res., 62: 1083-1086, 2002.
40. Wang, C. Y., Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med., 5: 412-417, 1999.
41. Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperdino]-carbonyloxy-camptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res., 60: 2323-2330, 2000.
42. Shah, S. A., Potter, M. W., McDade, T. P., Ricciardi, R., Perugini, R. A., Elliott, P. J., Adams, J., and Callery, M. P. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem., 82: 110-122, 2001.
43. Bassan, R., Lerede, T., Borieri, G., Chiodini, B., Rossi, A., Buelli, M., Rambaldi, A., Viero, P., and Barbui, T. Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin-A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia. Haematologica, 87: 257-263, 2002.
44. Hirsch-Ernst, K. I., Ziemann, C., Rustenbeck, I., and Kahl, G. F. Inhibitors of mdr1-dependent transport activity delay accumulation of the mdr1 substrate rhodamine 123 in primary rat hepatocyte cultures. Toxicology, 167: 47-57, 2001.
45. Lum, B. L., Kaubisch, S., Fisher, G. A., Brown, B. W., and Sikic, B. I. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Cancer Chemother. Pharmacol., 45: 305-311, 2000.
46. Bentires-Alj, M., Barbu, V., Fillet, M., Chariot, A., Relic, B., Jacobs, N., Gielen, J., Merville, M. P., and Bours, V. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 22: 90-97, 2003.
47. Kuo, M. T., Liu, Z., Wei, Y., Lin-Lee, Y. C., Tatebe, S., Mills, G. B., and Unate, H. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling. Oncogene, 21: 1945-1954, 2002.
48. Zhou, G., and Kuo, M. T. NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J. Biol. Chem., 272: 15174-15183, 1997.
49. Yamada, T., Mori, Y., Hayashi, R., Takada, M., Ino, Y., Naishiro, Y., Kondo, T., and Hirohashi, S. Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. Cancer Res., 63: 895-901, 2003.
50. Kusaba, H., Nakayama, M., Harada, T., Nomoto, M., Kohno, K., Kuwano, M., and Wada, M. Association of 5′ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur. J. Biochem., 262: 924-932, 1999.
51. Kolfschoten, G. M., Hulscher, T. M., Duyndam, M. C., Pinedo, H. M., and Boven, E. Variation of the kinetics of caspase-3 activation. Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem. Pharmacol., 63: 733-743, 2002.